Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MET Study of metformin maintenance therapy for newly diagnosed glioblastoma
jRCTs031200326Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2020
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metformin and temozolomide in glioblastoma (GBM), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Dose-limiting toxicity occurrence rate and 12-month progression-free survival rate. Started Nov 2020; status: active, not recruiting.
02
Drugs
metformintemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on jRCTs031200326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200326.